Improved Product Quality of Biosimilars in the Cellca CHO Expression Platform

15th December 2017

Category: Biosimilars

Tags: ,

By: Cornelia Lindner - Team Leader, Dr Christoph Zehe - Lead Scientist, Johannes Wirth - Scientist, Marina Putanko - Scientist,

Due to the high number of patent expirations for first generation biopharmaceuticals, the production of biosimilars is a fast growing market. Biosimilars require finger-print like similarity to their originator drug with respect to product quality.  One important aspect of product quality is a comparable glycosylation pattern, as glycosylation influences serum clearance, immunogenicity, as well as activity.

The α-2,6 sialyltransferase is essential for terminal sialylation. However, CHO DG44 cells lack the α-2,6 sialyltransferase, therefore, in many cases sialylation is one of the glycosylation parameters which differs most from the originator when biosimilars are expressed in CHO DG44. Although the standard Cellca CHO DG44 host shows a rather weak sialylation, the top 12 clones of our glycoengineering approach showed a sialylation pattern highly similar to the originator drug (Figure 1).

Want to know how we achieved an increased sialylation? Click here to download our scientific poster.

glycoengineering - Cellca CHO ExpressionFigure 1: Sialylation profile of originator, Cellca’s standard CHO DG44 and top 12 clones after glycoengineering. 

 

 

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy